PHK
DNTH icon

Point72 Hong Kong’s Dianthus Therapeutics DNTH Stock Holding History

Point72 Hong Kong’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-46
Closed -$6K – 1891
2020
Q4 		$6K Sell
46
-23
-33% -$2.61K ﹤0.01% 1578
2020
Q3 		$7K Buy
+69
New +$8.18K ﹤0.01% 1028
2018
Q3 		– Sell
-506
Closed -$109K – 965
2018
Q2 		$109K Buy
+506
New +$114K 0.04% 289

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Hong Kong's DNTH Position: Q1 2021 in Review

Point72 Hong Kong sold out of Dianthus Therapeutics (DNTH) in Q1 2021, closing a stake of 46 shares — an estimated $6K sold.

Point72 Hong Kong first reported a position in DNTH in Q2 2018 and held it in 3 quarters. The position peaked at $109K in Q2 2018. 90 funds tracked by Wall St. Rank hold DNTH as of Q1 2021.

  • Point72 Hong Kong reported no remaining Dianthus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Point72 Hong Kong sold 46 Dianthus Therapeutics shares in Q1 2021, an estimated $6K.
  • Point72 Hong Kong first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 3 quarters.
  • Point72 Hong Kong's Dianthus Therapeutics position peaked at $109K in Q2 2018.
  • 90 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2021.

Based on Point72 Hong Kong's 13F filing for Q1 2021, filed 17 May 2021.